Xbrane Biopharma publishes 2017 Annual Report






Press release

Xbrane Biopharma AB's annual report for 2017 is now available at the company's website, www.xbrane.com. The annual report is distributed to the shareholders and others that made such request. The annual report can also be ordered from Xbrane Biopharma on the following address:

Xbrane Biopharma AB
Banvaktsvägen 22
17148 Solna

Or via e-mail: ir@xbrane.com

About Xbrane
Xbrane Biopharma AB is a biotechnology company which develops, manufactures and produces commercial biosimilars. Xbrane has a patented protein production platform for development of biosimilars and world-leadingexpertise within biosimilars. Xbrane's head office is located in Solna, just outside Stockholm, and the company has research and development facilities in Sweden and in Italy. Xbrane has been listed on Nasdaq First North since 3 February 2016 under the name of XBRANE. Avanza Bank AB is Xbrane's Certified Adviser. For more information please visitwww.xbrane.com.

For further information, please contact:
Martin Åmark
Chief Executive Officer
M: +46 (0) 763-093 777
E: martin.amark@xbrane.com

Susanna Helgesen
CFO/IR, Xbrane Biopharma AB
M: +46 (0) 708-278 636
E: susanna.helgesen@xbrane.com

Xbrane publishes Annual Report for 2017

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Xbrane Biopharma AB via Globenewswire